alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › decreases-tau

decreases-tau

2 studies tagged decreases-tau, dated 2005-10-14 to 2023-04-20. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS 2023-04-20
  2. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies 2005-10-14

Studies

2 studies carry this tag.

Date range

2005 to 2023

Top journals

  • Acta neuropathologica 1
  • Annals of neurology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Annals of neurology 2023-04-20 Drug development

    In this study, suvorexant acutely decreased tau phosphorylation and amyloid-β concentrations in the central nervous system.

  2. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Acta neuropathologica 2005-10-14 Drug development

    Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases.

All topic tags with their study counts